Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
Adaptimmune Therapeutics (NASDAQ: ADAP), a pioneer in solid tumor cancer cell therapy treatments, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference in New York, NY. The company's CEO, Adrian Rawcliffe, will engage in a fireside chat on February 6, 2025, at 3:00 p.m. EST.
The event will be accessible via webcast, and interested parties can join through the provided link or through the 'Events' section under the 'News Center' tab in the 'Investors & Media' area of Adaptimmune's website. A replay of the presentation will be available after the event.
Adaptimmune Therapeutics (NASDAQ: ADAP), un pioniere nelle terapie cellulari per il cancro ai tumori solidi, ha annunciato la sua prossima partecipazione alla Guggenheim Securities SMID Cap Biotech Conference a New York, NY. Il CEO dell'azienda, Adrian Rawcliffe, parteciper脿 a una chiacchierata informale il 6 febbraio 2025, alle 15:00 EST.
L'evento sar脿 accessibile via webcast, e le parti interessate possono unirsi attraverso il link fornito o nella sezione 'Eventi' del tab 'News Center' nell'area 'Investitori e Media' del sito web di Adaptimmune. Una registrazione della presentazione sar脿 disponibile dopo l'evento.
Adaptimmune Therapeutics (NASDAQ: ADAP), un pionero en terapias celulares para el c谩ncer de tumores s贸lidos, ha anunciado su pr贸xima participaci贸n en la Guggenheim Securities SMID Cap Biotech Conference en Nueva York, NY. El CEO de la compa帽铆a, Adrian Rawcliffe, participar谩 en una charla informal el 6 de febrero de 2025, a las 3:00 p.m. EST.
El evento ser谩 accesible a trav茅s de webcast, y las partes interesadas pueden unirse a trav茅s del enlace proporcionado o en la secci贸n 'Eventos' bajo la pesta帽a 'News Center' en el 谩rea de 'Inversores y Medios' del sitio web de Adaptimmune. Una repetici贸n de la presentaci贸n estar谩 disponible despu茅s del evento.
Adaptimmune Therapeutics (NASDAQ: ADAP)電� 瓿犿槙鞎� 靹疙彫旃橂鞚� 靹犼惮鞛愲, 雺挫殨鞐愳劀 鞐措Μ電� Guggenheim Securities SMID Cap Biotech Conference鞐� 瓿� 彀胳棳頃� 瓴冹澊霛缄碃 氚滍憸頄堨姷雼堧嫟. 須岇偓鞚� CEO鞚� Adrian Rawcliffe電� 2025雲� 2鞗� 6鞚� 鞓ろ泟 3鞁� EST鞐� 牍勱车鞁� 雽�頇旍棎 彀胳劃頃� 鞓堨爼鞛呺媹雼�.
鞚� 鞚措菠韸鸽姅 鞗轨簮鞀ろ姼毳� 韱淀暣 鞝戧芳頃� 靾� 鞛堨溂氅�, 甏�鞁� 鞛堧姅 攵勲摛鞚� 鞝滉车霅� 毵來伂雮� Adaptimmune 鞗轨偓鞚错姼鞚� '韴瀽鞛� 氚� 氙鸽敂鞏�' 鞓侅棴鞚� '雺挫姢 靹柬劙' 韮� 鞎勲灅 '鞚措菠韸�' 靹轨厴鞚� 韱淀暣 彀胳棳頃� 靾� 鞛堨姷雼堧嫟. 氚滍憸鞚� 鞛儩鞚� 鞚措菠韸� 鞚错泟鞐� 鞝滉车霅� 鞓堨爼鞛呺媹雼�.
Adaptimmune Therapeutics (NASDAQ: ADAP), un pionnier dans les traitements de th茅rapie cellulaire contre les cancers des tumeurs solides, a annonc茅 sa prochaine participation 脿 la Guggenheim Securities SMID Cap Biotech Conference 脿 New York, NY. Le PDG de l'entreprise, Adrian Rawcliffe, participera 脿 une discussion informelle le 6 f茅vrier 2025 脿 15h00 EST.
L'茅v茅nement sera accessible par webcast, et les parties int茅ress茅es peuvent y assister via le lien fourni ou dans la section '脡v茅nements' sous l'onglet 'Centre de Nouvelles' dans la zone 'Investisseurs & M茅dias' du site web d'Adaptimmune. Une rediffusion de la pr茅sentation sera disponible apr猫s l'茅v茅nement.
Adaptimmune Therapeutics (NASDAQ: ADAP), ein Pionier in der Zelltherapie bei soliden Tumoren, hat seine bevorstehende Teilnahme an der Guggenheim Securities SMID Cap Biotech Conference in New York, NY, angek眉ndigt. Der CEO des Unternehmens, Adrian Rawcliffe, wird am 6. Februar 2025 um 15:00 Uhr EST an einem informellen Gespr盲ch teilnehmen.
Die Veranstaltung wird 眉ber ein Webcast zug盲nglich sein, und interessierte Parteien k枚nnen 眉ber den bereitgestellten Link oder im 'Ereignisse'-Bereich unter dem 'News Center'-Tab im Bereich 'Investoren & Medien' der Website von Adaptimmune teilnehmen. Eine Wiederholung der Pr盲sentation wird nach der Veranstaltung verf眉gbar sein.
- None.
- None.
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in the Guggenheim Securities SMID Cap Biotech Conference this February.
- Guggenheim Securities SMID Cap Biotech Conference, New York, NY
- Fireside chat with Adrian Rawcliffe, CEO: February 6 at 3:00 p.m. EST
- Webcast link:
This event can also be accessed by visiting 'Events', under the 'News Center' tab, in the 'Investors & Media' section of Adaptimmune's website at . Following the event, a replay of the presentation will be made available.
About Adaptimmune
Adaptimmune is a fully integrated cell therapy company working to redefine how cancer is treated. With its unique engineered T cell receptor (TCR) platform, the Company is developing personalized medicines designed to target and destroy difficult-to-treat solid tumor cancers and to radically improve the patient's cancer treatment experience.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended 31 December, 2023, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contact
Investor Relations
Juli P. Miller, Ph.D. - VP, Corporate Affairs and Investor Relations
T : +1 215 825 9310
M : +1 215 460 8920
[email protected]
Media Relations
Dana Lynch, Senior Director of Corporate Communications
M: +1 267 990 1217
[email protected]
To view the source version of this press release, please visit
FAQ
When is Adaptimmune's (ADAP) presentation at the Guggenheim Securities SMID Cap Biotech Conference 2025?
How can investors watch Adaptimmune's (ADAP) Guggenheim Securities conference presentation?
Will there be a replay available of Adaptimmune's (ADAP) Guggenheim Securities conference presentation?
What type of event will Adaptimmune (ADAP) participate in at the Guggenheim Securities conference?
